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OBJECTIVE—To examine the prevalence and incidence of unrecognized myocardial infarc-
tion in a contemporary population with type 2 diabetes.
RESEARCH DESIGN ANDMETHODS—We performed a retrospective analysis of the
electrocardiograms (ECGs) recorded at baseline and after 2 years for the ﬁrst 1,004 type 2 di-
abetic individuals to be randomized in the Rosiglitazone Evaluated for Cardiac Outcomes and
Regulation of Glycemia in Diabetes (RECORD) study.
RESULTS—ECGs suitable for analysis were obtained from 669 participants. The prevalence of
unrecognized Q-wave myocardial infarction at baseline was 1.9% (n = 13). The incidence of
unrecognized Q-wave myocardial infarction at the end of 2 years of follow-up was 1.5/1,000-
person-years (n = 2). One-third (13 of 39) of prevalent and one-quarter (2 of 8) of incident
myocardial infarctions were unrecognized.
CONCLUSIONS—Although the prevalence and incidence of myocardial infarction was low,
unrecognized Q-wave myocardial infarctions made up a substantial proportion of all events.
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A lthough usually accompanied bytypical symptoms, somemyocardialinfarctions (MIs) are not clinically
recognized. Unrecognized MIs are thought
to be important because there is some
evidence that they carry a similar prog-
nosis to recognized MIs (1–3). People
with diabetes are considered to be more
at risk for unrecognized MIs than those
without diabetes, but few data have di-
rectly addressed this issue. Consequently,
we examined the prevalence and inci-
dence of clinically unrecognized MI in a
contemporary population with type 2
diabetes enrolled in the Rosiglitazone
Evaluated for Cardiac Outcomes and
Regulation of Glycemia in Diabetes
(RECORD) study.
RESEARCH DESIGN AND
METHODS—The design of the
RECORD study has been described in
detail previously (4). In brief, the RECORD
study enrolled 4,458 people with type 2
diabetes that was inadequately controlled
with metformin or sulfonylurea monother-
apy. History of MI was obtained from the
trial case-report forms completed by the
study investigators.
This report describes a retrospective
analysis of the electrocardiograms (ECGs)
recorded at baseline and after 2 years in
the study for the ﬁrst 1,004 people to be
randomized. The ECG recordings were
coded independently by two cardiologists
using a list derived from the Minnesota
Code Classiﬁcation System for Electro-
cardiographic Findings. When the two
cardiologists did not agree, the ECG was
reviewed by a third cardiologist. A fourth
cardiologist reviewed all ECGs that were
identiﬁed with potential features of MI
and made the ﬁnal decision whether the
ECG demonstrated an MI.
A prevalent unrecognized Q-wave MI
was deﬁned as aQwave (Minnesota codes
1-1 through 1-2 only) in the absence of a
previous clinical history of MI at baseline
(1,5–9). An incident unrecognized Q-wave
MI was deﬁned as a Q wave (Minnesota
codes 1-1 through 1-2 only) in the absence
of an event as adjudicated by the end point
committee using European Society of Car-
diology deﬁnitions during the course of the
study (5,6,8,9). The incident population
only included people without Q waves on
their baseline ECG.
Data have been summarized for the
combined treatment groups using simple
descriptive statistics. Incidence rates per
1,000 person-years of follow-up have
been calculated as the number of people
with an event during the ﬁrst 2 years of
follow-up/total person-years.
RESULTS—The analysis excluded 335
of the 1,004 randomized people: 25 had
no baseline ECG, 99 had no ECG at 2
years, 82 withdrew from study, 16 died
during follow-up (7 were adjudicated as
cardiovascular deaths), ECGs for four
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individuals were not available for un-
known reasons, and 109 ECGs were not
suitable for 12-lead analysis. ECGs were
available and suitable for analysis at base-
line and at 2 years for 669 people, and
Q waves were present in 21 on their base-
line ECG. Therefore, 648 people (with no
Qwaves at baseline) were evaluable for the
incidence rate calculation of MIs. Table 1
describes the baseline characteristics of
the 669 people included in this analysis.
A history of MI was ascertained in 26
participants (3.9% [95% CI 2.6–5.7]). Of
these, eight had a Q wave present on their
baseline ECG, and 18 had no Q wave.
Q waves were present on the baseline
ECG (i.e., an unrecognized Q-wave MI) in
13 people (1.9% [1.1–3.3]) with no history
of MI. The overall prevalence of MI,
identiﬁed by history or ECG criteria
(recognized Q-wave/non–Q-wave MI +
unrecognized Q-wave MI), was 5.8%
(4.3–7.9; n = 39). Unrecognized Q-wave
MIs constituted 33% of all of these MIs.
Among the 648 people with no
Q waves at baseline, there were six adju-
dicated MIs, one of which resulted in a
Q wave, and Q waves developed in an
additional two people that were not asso-
ciated with an adjudicated MI (i.e., two
people had an unrecognized Q-wave MI).
The incidence of unrecognized Q-wave
MI was 1.5 (95% CI 0.0–3.6)/1,000
person-years, and unrecognized Q-wave
MIs accounted for two of eight (25%)
of all incident MIs documented using
both approaches. The incidence of any
detected MI during the 2-year period
was 8 of 648 or 6.2 (1.9–10.4)/1,000
person-years.
CONCLUSIONS—In absolute num-
bers, the prevalence and incidence of un-
recognized Q-wave MIs were low in this
substudyofRECORD,butbecause theprev-
alence and incidence of recognized MI was
also low, a notable proportion of all de-
tectedMIswere unrecognizedQ-waveMIs:
33% of prevalent MIs and 25% of incident
MIs were unrecognized Q-wave MIs.
An Australian prospective observa-
tional cohort study (n = 1,269) is the
only other study to examine the preva-
lence of unrecognized Q-wave MI in a co-
hort with type 2 diabetes. The prevalence
of unrecognized Q-wave MI was 3.9%,
making up 44% of all Q-wave MIs (7).
Three previous studies have exam-
ined the incidence of unrecognized MI
in people with diabetes (5,10,11). All
reported a higher incidence of unrecog-
nized MI than in this RECORD cohort.
The greater absolute prevalence and inci-
dence of unrecognizedMI in other studies
most likely reﬂects the higher rates of
cardiovascular disease at baseline. We
acknowledge that ours is a relatively
young clinical trial cohort, with small
numbers of participants and events. Our
ﬁndings may be subject to some uncer-
tainty and may not be applicable to older,
unselected populations with diabetes.
Most previous studies of “unrecognized
MI” have used the presence of Q waves to
indicate an event (12).Webelieve thatmany
unrecognized MIs will be missed by the re-
quirement of a Q wave. In our own popu-
lation, only 8 of 26 patients with a baseline
history of MI had Q waves, and only 1 of 6
adjudicated incident MIs resulted in a
Q wave on the ECG. Any study using
ECG criteria, and particularly Q waves
only, is therefore likely to considerably un-
derestimate the true burden of disease. Be-
cause of uncertainty about the validity of a
diagnosis of MI solely based on ECG ﬁnd-
ings, clinical deﬁnitions in line with Euro-
pean Society of Cardiology guidelines were
used to adjudicate events in RECORD (4).
Thus, although including unrecognized
Q-wave MIs would have increased the
number of events, we judged that they
would not add to the rigor of the study.
We found in this analysis of people
with diabetes in the RECORD study that
unrecognized Q-wave MIs made up a
substantial proportion of all detected
MIs. In view of the small numbers in
Table 1—Baseline characteristics
Variable n (%) Mean (SD)
Total population 669 —
Male 346 (51.7) —
Age (years) — 58.8 (8.2)
White 666 (99.6) —
Duration of diabetes (years) — 7.2 (5.2)
Physiologic measurements — —
BMI (kg/m2) — 31.2 (4.6)
Systolic blood pressure (mmHg) — 139.7 (15.4)
Diastolic blood pressure (mmHg) — 83.1 (8.9)
Heart rate (bpm) — 73.8 (8.4)
Medical history — —
Angina-stable 66 (9.9) —
Clinical history of MI 26 (3.9) —
Hypertension 541 (80.9) —
Hyperlipidemia 106 (15.8) —
Percutaneous coronary intervention 11 (1.6) —
Coronary artery bypass grafting 13 (1.9) —
Transient ischemic attack 13 (1.9) —
Stroke 13 (1.9) —
Peripheral arterial disease 21 (3.1) —
Diabetic retinopathy 80 (12) —
Heart failure 5 (0.7) —
Current smoker 103 (15.4) —
Previous smoker 146 (21.8) —
Neuropathy 38 (5.7) —
Laboratory measurements — —
HbA1c (%) — 7.9 (0.7)
Fasting plasma glucose (mmol/L) — 9.8 (2.2)
Total cholesterol (mmol/L) — 5.4 (1.0)
Microalbuminuria 96 (14.3) —
Macroalbuminuria 8 (1.2) —
Drug therapy —
Metformin monotherapy 344 (51.4) —
Sulfonylurea monotherapy 325 (48.6) —
Statin 110 (16.4) —
b-Blocker 161 (24.2) —
Angiotensin-converting enzyme inhibitor 257 (38.4) —
Antiplatelet 144 (21.5) —
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our analysis, further studies (or meta-
analyses of studies) are needed to conﬁrm
(or refute) our ﬁndings and recommend
how best to establish the true burden of
MI in people with diabetes.
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